Faron Reports 85% Response Rate in Higher-Risk MDS Trial
Faron reported an 85% response rate in a frontline higher-risk MDS trial of a bexmarilimab combination.
Related stories
Window Asia to Acquire 76,000 Shares in Quad The Interior Company
M impact | EQUITY | Nov 04, 2026, 03:06 PM UTC
BIOREM Reports Q3 Earnings of CA$0.14
BIOREM reported third-quarter earnings of CA$0.14.
M impact | EQUITY | Nov 04, 2026, 03:06 PM UTC
NYSE American single-stock trading halt, symbol not given — additional information requested (last $21.15)
NYSE American halted trading in a single listed security (additional information requested). Last price $21.15.
L impact | EQUITY | Nov 04, 2026, 03:06 PM UTC
Thai Optical Posts Quarterly Net Profit of 168 Million Baht
M impact | EQUITY | Nov 04, 2026, 03:05 PM UTC
US Stocks Rise After Democratic Election Win; Clean-Energy Shares in Demand
Reuters reports that a Democratic election victory boosted US stocks and lifted demand for clean-energy shares.
M impact | EQUITY | Nov 04, 2026, 03:05 PM UTC
Wall Street Rallies After Democrats Win Congress; Data Center Stocks Slide
U.S. stocks rose as investors anticipated that a divided Washington could limit sharp policy shifts. Data center stocks fell amid concerns about tighter AI regulation.
M impact | EQUITY | Nov 04, 2026, 03:05 PM UTC